Pàgina 1 des de 108 resultats
BACKGROUND OF THE INVENTION
Field of the Invention
The invention generally relates to compositions and methods to increase the ability of hypoxia-activated bioreductive agents to kill tumor cells within solid tumors. In particular, the invention provides methods and compositions to create local
BACKGROUND OF THE INVENTION
Field of the Invention
The invention generally relates to compositions and methods to increase the ability of hypoxia-activated bioreductive agents to kill tumor cells within solid tumors. In particular, the invention provides methods and compositions to create local
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention generally relates to compositions and methods to increase the ability of hypoxia-activated bioreductive agents to kill tumor cells within solid tumors. In particular, the invention provides methods and compositions to create local
BACKGROUND OF THE INVENTION
Field of the Invention
The invention generally relates to compositions and methods to increase the ability of hypoxia-activated bioreductive agents to kill tumor cells within solid tumors. In particular, the invention provides methods and compositions to create local
BACKGROUND OF THE INVENTION
Field of the Invention
The invention generally relates to compositions and methods to increase the ability of hypoxia-activated bioreductive agents to kill tumor cells within solid tumors. In particular, the invention provides methods and compositions to create local
FIELD
Disclosed herein is {[5-(3-fluorophenyl)-3-hydroxypyridine-2-carbonyl]-amino}acetic acid and the ester and amide prodrugs thereof, that can stabilize hypoxia inducible factor-2 alpha (HIF-2.alpha.) and thereby provide a method for treating cancer. Further disclosed are compositions which
BACKGROUND OF THE INVENTION
The present invention is generally directed to treating tumors, and more particularly to a method of inducing hypoxia in tumors through the use of a magnetic fluid.
Tumors consist of a core of hypoxic (low oxygen) cells surrounded by a mass of non-hypoxic cells. The
The present invention relates to the finding of a novel interaction between the VHL and HIF proteins, assays based upon this interaction and novel compounds obtainable by such assay methods.
BACKGROUND TO THE INVENTION
Enhanced glucose metabolism and angiogenesis are classical features of cancer
The present invention relates to the finding of a novel interaction between the VHL and HIF proteins, assays based upon this interaction and novel compounds obtainable by such assay methods.
BACKGROUND TO THE INVENTION
Enhanced glucose metabolism and angiogenesis are classical features of cancer
FIELD OF THE INVENTION
The present invention provides methods and compositions for treating cancer with hypoxia activated prodrugs administered alone and in combination with anticancer drugs that are not hypoxically activated and/or in combination with radiation therapy. The invention relates to the
FIELD OF THE DISCLOSURE
This disclosure concerns agents that transiently decrease the partial pressure of oxygen in a tumor and methods of using them to increase the efficacy of hypoxia-sensitive agents to treat subjects with a tumor.
BACKGROUND
Hypoxia within regions of solid tumors is associated
FIELD OF THE INVENTION
The present invention provides methods for treating cancer, and pharmaceutical formulations and unit dose forms useful in those methods. The invention therefore relates to the fields of medicine and pharmacology.
BACKGROUND OF THE INVENTION
TH-302 is a hypoxia-activated
FIELD OF THE INVENTION
This invention relates to epidithiodiketopiperazine compounds, pharmaceutical compositions based thereon and methods of treating, reducing or inhibiting transcription and translation of hypoxia-inducible genes.
BACKGROUND OF THE INVENTION
The high rate of cancer morbidity and
FIELD OF INVENTION
The present invention relates to a method for determining the oxygen status of cancer, wherein the determination is based on transcriptional expression level of gene(s) differentially expressed in varying levels of oxygen. The invention also pertains to a method for treatment of
TECHNICAL FIELD
The present invention relates to nanoparticles that change their properties under hypoxic conditions, and thus can be used for the diagnosis and treatment of hypoxia-related diseases.
BACKGROUND ART
Hypoxia, a pathological condition deprived of adequate oxygen supply, is a hallmark